Search
Vespula maculifrons venom protein
go.drugbank.com/drugs/DB10956ApprovedVespula maculifrons venom protein is an extract of Vespula maculifrons venom. Vespula maculifrons venom protein is used in allergenic testing.
Polistes annularis venom protein
go.drugbank.com/drugs/DB11027ApprovedPolistes annularis venom protein is an extract of Polistes annularis venom. Polistes annularis venom protein is used in allergenic testing.
Vespula germanica venom protein
go.drugbank.com/drugs/DB11030ApprovedVespula germanica venom protein is an extract of Vespula germanica venom. Vespula germanica venom protein is used in allergenic testing.
GLB-001
go.drugbank.com/drugs/DB32795InvestigationalGLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).[L56124, L56125, L56126]
Tetrahydrofolic acid
go.drugbank.com/drugs/DB00116InvestigationalNutraceuticalIt is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids. … Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase.
Asvasiran
go.drugbank.com/drugs/DB05638InvestigationalAsvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
HLX70
go.drugbank.com/drugs/DB16509Investigationalin healthy adult volunteers. … The condition targeted by HLX70 in this study is COVID-19.
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
go.drugbank.com/drugs/DB13948Experimental25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. … It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen.
Synonyms: NBOH-2C-CN, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineBrasofensine
go.drugbank.com/drugs/DB04857ExperimentalIn November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.